2024-516477-73-00Active, not recruitingPhase 1
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
Source: EU CTIS (euclinicaltrials.eu) · Last updated 29 Sept 2026
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 320 (estimated)
- First submitted
- 21 Aug 2024
- Start date
- 7 Mar 2018
- Lead sponsor
- Exelixis Inc.
- Diseases
- Bladder cancer, Kidney cancer
- EU CT number
- 2024-516477-73-00
- EudraCT number
- 2017-001792-24
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 320
- 6 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (6)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Catala d'Oncologia | Badalona | Spain | Active, not recruiting |
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Active, not recruiting |
| Hospital Clinic de Barcelona | Barcelona | Spain | Active, not recruiting |
| Hospital Universitario Ramón y Cajal | Madrid | Spain | Active, not recruiting |
| Hospital Universitario 12 de Octubre | Madrid | Spain | Active, not recruiting |
| Institut Gustave Roussy | Villejuif | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.